Post by Roswell Park Comprehensive Cancer Center

Exciting research happening at AACR on Sunday! Preclinical research by Gokul Das, PhD, Professor of Oncology and Co-Director of the Breast Translational Research Group, and colleagues has revealed a novel combination therapy with the potential to make inroads against metastatic triple-negative breast cancer (mTNBC), an aggressive and hard-to-treat subtype. Dr. Das, first and presenting author, will share the findings in the late-breaking abstract LB058/11, “Clinically actionable drug synergy drives transcriptomic and metabolic reprogramming to induce ferroptosis and apoptosis in triple negative breast cancer” Sunday, April 19, 2-5 p.m., in Section 52 of the Convention Center. “Our discovery in the lab shows that an existing drug that is not currently used to treat triple-negative breast cancer has the potential to become highly effective when paired with a generic chemotherapy drug, creating a therapy that is both cost-effective and less toxic,” explains Dr. Das. “In our preclinical study, we found that this combination works better than the sum of the effects of the component drugs — one plus one is more than two. By repurposing existing drugs, we can accelerate the path to the clinic, use lower doses and potentially reduce side effects and disease resistance.”